C4 Therapeutics (CCCC) Operating Margin (2019 - 2025)
Historic Operating Margin for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 306.43%.
- C4 Therapeutics' Operating Margin fell 1225700.0% to 306.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 431.07%, marking a year-over-year decrease of 766300.0%. This contributed to the annual value of 336.15% for FY2024, which is 3336900.0% up from last year.
- C4 Therapeutics' Operating Margin amounted to 306.43% in Q3 2025, which was down 1225700.0% from 440.99% recorded in Q2 2025.
- Over the past 5 years, C4 Therapeutics' Operating Margin peaked at 75.98% during Q4 2021, and registered a low of 1410.21% during Q2 2023.
- Moreover, its 5-year median value for Operating Margin was 402.93% (2025), whereas its average is 545.7%.
- Its Operating Margin has fluctuated over the past 5 years, first tumbled by -12657500bps in 2022, then surged by 12316200bps in 2024.
- Quarter analysis of 5 years shows C4 Therapeutics' Operating Margin stood at 75.98% in 2021, then crashed by -1666bps to 1341.73% in 2022, then increased by 14bps to 1147.72% in 2023, then skyrocketed by 37bps to 728.39% in 2024, then surged by 58bps to 306.43% in 2025.
- Its Operating Margin stands at 306.43% for Q3 2025, versus 440.99% for Q2 2025 and 402.93% for Q1 2025.